Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27950 | 0.80 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5480102 | 0.76 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL1817573 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3305715 | 0.72 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL448747 | 0.67 | HDAC6 (0.34) | — | |
| SCHEMBL1035174 | 0.67 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL11378113 | 0.66 | — | — | |
| SCHEMBL27949 | 0.65 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2224744 | 0.64 | — | — | |
| SCHEMBL569156 | 0.63 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546610-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | claimed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| EP-2103601-B1 | PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION | AJINOMOTO KK (JP) | 2012-03-14 | — | — | EP | claimed |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-12-22 | — | — | US | claimed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | claimed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | claimed |
| EP-2103601-A1 | PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION | Ajinomoto Co., Inc. (JP) | 2009-09-23 | — | — | EP | claimed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | claimed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | claimed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | claimed |
| WO-2005018642-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MYOCARDITIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | WO | claimed |
| US-20050043318-A1 | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | SCHERING AKTIEGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | claimed |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | US | claimed |
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | claimed |
| US-6555537-B2 | Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | claimed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | claimed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | claimed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | claimed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | claimed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | ALDH1A1 465/4885SMN1; SMN2 4729/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | ALDH1A1 1361/4885SMN1; SMN2 4250/4885 |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | PAH, DDC, AADAT | ALDH1A1 985/4885SMN1; SMN2 4096/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | ALDH1A1 465/4885SMN1; SMN2 4729/4885 |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | ALDH1A1 465/4885SMN1; SMN2 4729/4885 |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | PAH, DDC, ASNS | ALDH1A1 1454/4885SMN1; SMN2 4006/4885 |
| US-20050043318-A1 | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | CCL2, CCR2, CXCL10 | ALDH1A1 1361/4885SMN1; SMN2 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.